PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: The bad berka experience since 2013

Harshad R. Kulkarni; Aviral Singh; Christiane Schuchardt; Karin Niepsch; Manal Sayeg; Yevgeniy Leshch; Hans Juergen Wester; Richard P. Baum

doi:10.2967/jnumed.115.170167

PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: The bad berka experience since 2013

Harshad R. Kulkarni
, Aviral Singh
, Christiane Schuchardt
, Karin Niepsch
, Manal Sayeg
, Yevgeniy Leshch
, Hans Juergen Wester
, Richard P. Baum

Associate Professorship of Pharmaceutical Radiochemistry

Zentralklinik Bad Berka

Research output: Contribution to journal › Article › peer-review

175 Scopus citations

Abstract

A potential milestone in personalized nuclear medicine is theranostics of metastatic castration-resistant prostate cancer (mCRPC) based on molecular imaging using PET/CT with ⁶⁸Ga-labeled prostate-specific membrane antigen (PSMA) ligands and molecular radiotherapy using PSMA-targeted radioligand therapy (PRLT) with ¹⁷⁷Lu-PSMA ligands. ⁶⁸Ga-PSMA PET/CT enables accurate detection of mCRPC lesions with high diagnostic sensitivity and specificity and provides quantitative and reproducible data that can be used to select patients for PRLT and therapeutic monitoring. Our comprehensive experience over the last 3 years using different radioligands indicates that PRLT is highly effective for the treatment of mCRPC, even in advanced cases, and potentially lends a significant benefit to overall and progression-free survival. Additionally, significant improvement in clinical symptoms and excellent palliation of pain can be achieved.

Original language	English
Pages (from-to)	97S-104S
Journal	Journal of Nuclear Medicine
Volume	57
DOIs	https://doi.org/10.2967/jnumed.115.170167
State	Published - 1 Oct 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

PSMA
Radioligand therapy
Theranostics

Access to Document

10.2967/jnumed.115.170167

Cite this

@article{7e530562edac419385bd054339282b4f,

title = "PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: The bad berka experience since 2013",

abstract = "A potential milestone in personalized nuclear medicine is theranostics of metastatic castration-resistant prostate cancer (mCRPC) based on molecular imaging using PET/CT with 68Ga-labeled prostate-specific membrane antigen (PSMA) ligands and molecular radiotherapy using PSMA-targeted radioligand therapy (PRLT) with 177Lu-PSMA ligands. 68Ga-PSMA PET/CT enables accurate detection of mCRPC lesions with high diagnostic sensitivity and specificity and provides quantitative and reproducible data that can be used to select patients for PRLT and therapeutic monitoring. Our comprehensive experience over the last 3 years using different radioligands indicates that PRLT is highly effective for the treatment of mCRPC, even in advanced cases, and potentially lends a significant benefit to overall and progression-free survival. Additionally, significant improvement in clinical symptoms and excellent palliation of pain can be achieved.",

keywords = "PSMA, Radioligand therapy, Theranostics",

author = "Kulkarni, \{Harshad R.\} and Aviral Singh and Christiane Schuchardt and Karin Niepsch and Manal Sayeg and Yevgeniy Leshch and Wester, \{Hans Juergen\} and Baum, \{Richard P.\}",

year = "2016",

month = oct,

day = "1",

doi = "10.2967/jnumed.115.170167",

language = "English",

volume = "57",

pages = "97S--104S",

journal = "Journal of Nuclear Medicine",

issn = "0161-5505",

publisher = "Society of Nuclear Medicine Inc.",

}

TY - JOUR

T1 - PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer

T2 - The bad berka experience since 2013

AU - Kulkarni, Harshad R.

AU - Singh, Aviral

AU - Schuchardt, Christiane

AU - Niepsch, Karin

AU - Sayeg, Manal

AU - Leshch, Yevgeniy

AU - Wester, Hans Juergen

AU - Baum, Richard P.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - A potential milestone in personalized nuclear medicine is theranostics of metastatic castration-resistant prostate cancer (mCRPC) based on molecular imaging using PET/CT with 68Ga-labeled prostate-specific membrane antigen (PSMA) ligands and molecular radiotherapy using PSMA-targeted radioligand therapy (PRLT) with 177Lu-PSMA ligands. 68Ga-PSMA PET/CT enables accurate detection of mCRPC lesions with high diagnostic sensitivity and specificity and provides quantitative and reproducible data that can be used to select patients for PRLT and therapeutic monitoring. Our comprehensive experience over the last 3 years using different radioligands indicates that PRLT is highly effective for the treatment of mCRPC, even in advanced cases, and potentially lends a significant benefit to overall and progression-free survival. Additionally, significant improvement in clinical symptoms and excellent palliation of pain can be achieved.

AB - A potential milestone in personalized nuclear medicine is theranostics of metastatic castration-resistant prostate cancer (mCRPC) based on molecular imaging using PET/CT with 68Ga-labeled prostate-specific membrane antigen (PSMA) ligands and molecular radiotherapy using PSMA-targeted radioligand therapy (PRLT) with 177Lu-PSMA ligands. 68Ga-PSMA PET/CT enables accurate detection of mCRPC lesions with high diagnostic sensitivity and specificity and provides quantitative and reproducible data that can be used to select patients for PRLT and therapeutic monitoring. Our comprehensive experience over the last 3 years using different radioligands indicates that PRLT is highly effective for the treatment of mCRPC, even in advanced cases, and potentially lends a significant benefit to overall and progression-free survival. Additionally, significant improvement in clinical symptoms and excellent palliation of pain can be achieved.

KW - PSMA

KW - Radioligand therapy

KW - Theranostics

UR - https://www.scopus.com/pages/publications/84991320867

U2 - 10.2967/jnumed.115.170167

DO - 10.2967/jnumed.115.170167

M3 - Article

C2 - 27694180

AN - SCOPUS:84991320867

SN - 0161-5505

VL - 57

SP - 97S-104S

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

ER -

PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: The bad berka experience since 2013

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this